Investment analysts at StockNews.com initiated coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a note issued to investors on Wednesday. The firm set a “buy” rating on the stock.
Several other brokerages also recently weighed in on MEIP. Laidlaw downgraded MEI Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Brookline Capital Management downgraded MEI Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 22nd. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, MEI Pharma presently has a consensus rating of “Hold” and an average target price of $7.00.
Read Our Latest Stock Report on MEIP
MEI Pharma Trading Up 1.6 %
Institutional Trading of MEI Pharma
A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI bought a new position in shares of MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned approximately 0.09% of MEI Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 52.38% of the stock is currently owned by institutional investors.
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Further Reading
- Five stocks we like better than MEI Pharma
- Do ETFs Pay Dividends? What You Need to Know
- Emerging Markets: What They Are and Why They Matter
- How to Calculate Return on Investment (ROI)
- Recession or Not, These 3 Stocks Are Winners
- What is Insider Trading? What You Can Learn from Insider Trading
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.